OBJECTIVES: We have previously demonstrated activity of Apo2L/TRAIL against patient pancreatic tumor xenografts. Here, we have examined the influence of the tumor implantation site on therapeutic response of orthotopic tumors and their metastases to Apo2L/TRAIL. METHODS: Sensitivity of 6 patient pancreatic tumor xenografts to Apo2L/TRAIL was determined in a subcutaneous model. To compare the response of orthotopic tumors, cells from subcutaneous xenografts were injected into the pancreas. Tumor growth was confirmed by histological examination of selected mice, and then treatment was started. When all control mice developed externally palpable tumors, the experiment was terminated, and pancreatic weights compared between control and treated groups. Magnetic resonance imaging was used to quantitate the response of orthotopic and metastatic tumors. RESULTS: The sensitivity to Apo2L/TRAIL observed in subcutaneous tumors was maintained in orthotopic tumors. Metastatic spread was observed with orthotopic tumor implantation. In an orthotopic model of a sensitive tumor, primary and metastatic tumor burden was significantly reduced, and median survival significantly extended by Apo2L/TRAIL therapy. CONCLUSIONS: Our data provide evidence that the site of tumor engraftment does not alter the inherent sensitivity of patient xenografts to Apo2L/TRAIL, and these results highlight the potential of Apo2L/TRAIL therapy against primary and metastatic pancreatic cancer.
OBJECTIVES: We have previously demonstrated activity of Apo2L/TRAIL against patientpancreatic tumor xenografts. Here, we have examined the influence of the tumor implantation site on therapeutic response of orthotopic tumors and their metastases to Apo2L/TRAIL. METHODS: Sensitivity of 6 patientpancreatic tumor xenografts to Apo2L/TRAIL was determined in a subcutaneous model. To compare the response of orthotopic tumors, cells from subcutaneous xenografts were injected into the pancreas. Tumor growth was confirmed by histological examination of selected mice, and then treatment was started. When all control mice developed externally palpable tumors, the experiment was terminated, and pancreatic weights compared between control and treated groups. Magnetic resonance imaging was used to quantitate the response of orthotopic and metastatic tumors. RESULTS: The sensitivity to Apo2L/TRAIL observed in subcutaneous tumors was maintained in orthotopic tumors. Metastatic spread was observed with orthotopic tumor implantation. In an orthotopic model of a sensitive tumor, primary and metastatic tumor burden was significantly reduced, and median survival significantly extended by Apo2L/TRAIL therapy. CONCLUSIONS: Our data provide evidence that the site of tumor engraftment does not alter the inherent sensitivity of patient xenografts to Apo2L/TRAIL, and these results highlight the potential of Apo2L/TRAIL therapy against primary and metastatic pancreatic cancer.
Authors: Belen Rubio-Viqueira; Antonio Jimeno; George Cusatis; Xianfeng Zhang; Christine Iacobuzio-Donahue; Collins Karikari; Chanjusn Shi; Kathleen Danenberg; Peter V Danenberg; Hidekazu Kuramochi; Koji Tanaka; Sharat Singh; Hossein Salimi-Moosavi; Nadia Bouraoud; Maria L Amador; Soner Altiok; Piotr Kulesza; Charles Yeo; Wells Messersmith; James Eshleman; Ralph H Hruban; Anirban Maitra; Manuel Hidalgo Journal: Clin Cancer Res Date: 2006-08-01 Impact factor: 12.531
Authors: N C Lee; M Bouvet; S Nardin; P Jiang; E Baranov; B Rashidi; M Yang; X Wang; A R Moossa; R M Hoffma Journal: Clin Exp Metastasis Date: 2000 Impact factor: 5.150
Authors: Mukund Seshadri; Mihai Merzianu; Haikuo Tang; Nestor R Rigual; Maureen Sullivan; Thom R Loree; Saurin R Popat; Elizabeth A Repasky; Bonnie L Hylander Journal: Cancer Biol Ther Date: 2009-12-19 Impact factor: 4.742
Authors: Bonnie L Hylander; Rose Pitoniak; Remedios B Penetrante; John F Gibbs; Dilek Oktay; Jinrong Cheng; Elizabeth A Repasky Journal: J Transl Med Date: 2005-05-19 Impact factor: 5.531
Authors: Erik S Knudsen; Vishnu Kumarasamy; Sejin Chung; Amanda Ruiz; Paris Vail; Stephanie Tzetzo; Jin Wu; Ram Nambiar; Jared Sivinski; Shailender S Chauhan; Mukund Seshadri; Scott I Abrams; Jianmin Wang; Agnieszka K Witkiewicz Journal: Gut Date: 2020-05-18 Impact factor: 23.059
Authors: Bonnie L Hylander; Arindam Sen; Sarah H Beachy; Rose Pitoniak; Soumya Ullas; John F Gibbs; Jingxin Qiu; Joshua D Prey; Gerald J Fetterly; Elizabeth A Repasky Journal: J Control Release Date: 2015-09-03 Impact factor: 9.776
Authors: Bora E Baysal; Abdulrahman A Alahmari; Tori C Rodrick; Debra Tabaczynski; Leslie Curtin; Mukund Seshadri; Drew R Jones; Sandra Sexton Journal: JCI Insight Date: 2022-09-08
Authors: Jason W-L Eng; Thomas A Mace; Rohit Sharma; Danielle Y F Twum; Peng Peng; John F Gibbs; Rosemarie Pitoniak; Chelsey B Reed; Scott I Abrams; Elizabeth A Repasky; Bonnie L Hylander Journal: J Immunother Cancer Date: 2016-06-21 Impact factor: 13.751